12-Month Net Income Growth: 7.6%
Cash Flow Multiple: 19 (68% peer premium)
Quarterly Operating Profit Margin: 54%
Analyst Opinions: Just three researchers follow Questcor, with two rating its stock "buy" and one ranking it "hold." Oppenheimer forecasts that the stock will advance 24% to $19. The shares certainly have technical momentum. They've appreciated 44% in the past three months. Acthar was recently approved by the FDA as a safe treatment for infantile spasms, expanding the drug's revenue potential. It is now approved to treat more than 29 disorders.